EricLawrenceSmithMD

PubMed

• The Future of Chimeric Antigen Receptor T Cell Therapy.
  Eric L Smith
  Hematology/oncology Clinics of North America. 2023-12-01
• Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.
  Malin Hultcrantz, Joshua Richter, Cara A. Rosenbaum, Dhwani Patel, Eric L. Smith
  Blood Cancer Discovery. 2020-11-04
• 10 citations
  Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells.
  Urvi A Shah, Eric L. Smith
  Cancer Journal. 2019-05-01

Abstracts/Posters

• MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRD) with or without Rivaroxaban Prophylaxis
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients ...
  Eric L Smith, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all